Clinical Trials
9 trialsNCT06925737 2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06780085 2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05067140 2026-05-05
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Phase 1/2 Active not recruiting
NCT02685826 2023-10-06
A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma
Celgene
Phase 1/2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT01414205 2017-04-17
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)
Genentech, Inc.
Phase 2 Completed
NCT00661102 2016-11-02
A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
Hoffmann-La Roche
Phase 3 Completed